Tag: radioembolization

radioembolization

Radioembolization with Y-90 now “a versatile treatment option” for HCC patients...

As presented at the Global Embolization Oncology Symposium Technologies (GEST) 2020 meeting (4–6 September, virtual), Robert Lewandowski discusses the evolution of radioembolization with Yttrium-90...
Y-90

Sirtex Medical completes enrollment of landmark US RESiN registry

Sirtex Medical reports that enrollment in the US RESiN registry has reached a milestone of 1,650 patients and 12.8 months of follow-up, allowing for...
radioembolization

Novel use of Y-90 radioembolization could transform prostate cancer treatment

In an entirely new endeavour for Yttrium-90 (Y-90) radioembolization, investigators from Northwestern University, Chicago, USA, have used the technique for the treatment of prostate...
Hepatology

Radioembolization paper publication a “landmark moment” for IR-Hepatology collaboration

The cover of June’s edition of the Journal of Hepatology featured a paper on transarterial radioembolization for the treatment of hepatocellular carcinoma (HCC). Publication...
radioembolization

Combining targeted Holmium-166 radioembolization with systemic therapy improves response rates in...

This article is sponsored by Terumo. The first prospective study on the combination of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and Holmium-166 (166Ho) radioembolization...
radiopaque

Novel radiopaque microspheres in Y-90 radioembolization show potential to map absorbed...

A proof-of-concept study has demonstrated the feasibility of using computed tomography (CT) with a novel composition of radiopaque microspheres in Yttrium-90 (Y-90) radioembolization to...
Interventional News for specialists

Patients prefer transradial access to transfemoral, study finds

Patients have a strong preference for transradial access, a recent study published in the Journal of Vascular and Interventional Radiology finds. Lead author Lisa...
Interventional News for specialists

Y90 radioembolization shows promise in treating metastatic pancreatic cancer

Encouraging results from Y90 (yttrium-90) radioembolization of pancreatic cancer support a possible role for it in the management of the disease, with initial small...
coil

A “mediocre success rate” found for coil embolization to obtain intrahepatic...

Coil embolization of hepatic arteries to induce redistribution of blood flow and microspheres has a mediocre success rate, concluded a recent study presented by...

Lessons from randomised controlled trials utilising SIRT in liver cancer

A recent session at CIRSE 2018 sought to go beyond the headline findings from a number of recent randomised controlled trials (RCTs) in interventional...
Hepatology

Radiation segmentectomy offers new treatment option for liver cancer

Radiation segmentectomy is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. One-, three-, and five-year overall survival probability was 100%, 82% and 75% in patients with a baseline tumour size of 3cm or less.

Varian signs agreement to acquire Sirtex

Varian Medical has announced it has signed an agreement to acquire all the outstanding shares of Sirtex Medical for A$28 per share in cash....

MIM software receives US FDA 510(k) clearance for post-treatment dosimetry of...

Dosimetry, within the context of selective internal radiation therapy (SIRT) using Y-90 microspheres, is typically understood to be the measurement and calculation of the...

REsect study shows SIRT makes metastatic colorectal cancer patients more likely...

Metastatic colorectal cancer patients treated first-line with SIR-spheres Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, the REsect study...

SIRT significantly better tolerated than sorafenib, but does not increase overall...

The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not...

Terumo announces first commercial clinical case using Quiremspheres

Terumo Europe NV has announced the first commercial clinical case using Quiremspheres—the next generation radioembolization microspheres for advanced unresectable liver cancer. Quiremspheres are the only...

The role of Y-90 radioembolization for cholangiocarcinoma

Y-90 radioembolization is a promising locoregional therapy for a devastating disease with few available treatment options. Ongoing and future clinical trials will help to...

Prevention and management of complications of Y-90 therapy

Most complications related to Y-90 therapy may be prevented or mitigated with appropriate patient selection, careful pretreatment planning, meticulous procedural technique, and optimisation of...

BTG and Mirada Medical announce CE mark certification for Simplicit90Y dosimetry...

BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy...

New ESMO biliary cancer guidelines indicate radioembolization as an option for...

New European Society of Medical Oncology (ESMO) biliary cancer guidelines indicate yttrium-90 (Y-90) therapy as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma. Sirtex has announced...